Raya Leibowitz‐Amit
About
Raya Leibowitz‐Amit is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Raya Leibowitz‐Amit has authored 80 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 24 papers in Surgery. Recurrent topics in Raya Leibowitz‐Amit's work include Prostate Cancer Treatment and Research (27 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Radiopharmaceutical Chemistry and Applications (16 papers). Raya Leibowitz‐Amit is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Radiopharmaceutical Chemistry and Applications (16 papers). Raya Leibowitz‐Amit collaborates with scholars based in Israel, Canada and United States. Raya Leibowitz‐Amit's co-authors include Arnoud J. Templeton, Ian F. Tannock, Jennifer J. Knox, Francisco Vera-Badillo, Michal Schwartz, Gila Moalem‐Taylor, Irun R. Cohen, Eitan Amir, Mairéad G. McNamara and Boštjan Šeruga and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Journal of Neuroscience.
In The Last Decade
Raya Leibowitz‐Amit
75 papers receiving 5.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Raya Leibowitz‐Amit Israel | 23 | 2.4k | 1.1k | 978 | 889 | 824 | 80 | 5.1k | ||
| Seunggu J. Han United States | 39 | 709 0.3× | 732 0.7× | 842 0.9× | 254 0.3× | 791 1.0× | 117 | 4.7k | ||
| Camilo E. Fadul United States | 34 | 1.4k 0.6× | 796 0.8× | 465 0.5× | 276 0.3× | 430 0.5× | 113 | 3.9k | ||
| Michael A. Gordon United States | 33 | 1.3k 0.6× | 625 0.6× | 214 0.2× | 399 0.4× | 1.1k 1.3× | 98 | 3.6k | ||
| N. Ferrara United States | 20 | 742 0.3× | 783 0.7× | 810 0.8× | 746 0.8× | 473 0.6× | 21 | 5.1k | ||
| Laura Fugazzola Italy | 46 | 1.3k 0.5× | 495 0.5× | 468 0.5× | 361 0.4× | 1.2k 1.4× | 188 | 6.7k | ||
| Wenche Jy United States | 41 | 511 0.2× | 759 0.7× | 1.4k 1.5× | 723 0.8× | 471 0.6× | 121 | 6.1k | ||
| Dirk Walter Germany | 37 | 984 0.4× | 778 0.7× | 602 0.6× | 861 1.0× | 2.5k 3.0× | 91 | 6.2k | ||
| Elisabeth M. Zeisberg Germany | 28 | 1.4k 0.6× | 1.1k 1.1× | 677 0.7× | 1.0k 1.2× | 1.1k 1.4× | 57 | 7.0k | ||
| Michael R. Harrison United States | 37 | 1.8k 0.8× | 2.9k 2.8× | 619 0.6× | 611 0.7× | 1.7k 2.1× | 176 | 6.1k | ||
| Jun‐ichi Hanai United States | 30 | 1.0k 0.4× | 632 0.6× | 901 0.9× | 1.1k 1.2× | 598 0.7× | 40 | 6.9k |
Countries citing papers authored by Raya Leibowitz‐Amit
Since
Specialization
Citations
This map shows the geographic impact of Raya Leibowitz‐Amit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raya Leibowitz‐Amit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raya Leibowitz‐Amit more than expected).
Fields of papers citing papers by Raya Leibowitz‐Amit
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Raya Leibowitz‐Amit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raya Leibowitz‐Amit. The network helps show where Raya Leibowitz‐Amit may publish in the future.
Co-authorship network of co-authors of Raya Leibowitz‐Amit
This figure shows the co-authorship network connecting the top 25 collaborators of Raya Leibowitz‐Amit. A scholar is included among the top collaborators of Raya Leibowitz‐Amit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raya Leibowitz‐Amit. Raya Leibowitz‐Amit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Harel, Michal, Igor Puzanov, Ronan J. Kelly, et al.. (2025). Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications. Journal for ImmunoTherapy of Cancer. 13(5). e011427–e011427.
2.
Rahbar, Kambiz, Michal Sarfaty, Raya Leibowitz‐Amit, et al.. (2024). 1629P Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra). Annals of Oncology. 35. S983–S984.
3.
Necchi, Andrea, Michiel S. van der Heijden, Avivit Peer, et al.. (2024). Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study. BMC Cancer. 23(S1). 1252–1252.
4.
Wiesel, Ory, Sook Whan Sung, Amit Katz, et al.. (2023). A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection. Biosensors. 13(6). 627–627.
5.
Furman, Orit, Moran Gadot, Damien Urban, et al.. (2021). Immune checkpoint inhibitors–related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. Supportive Care in Cancer. 29(12). 7563–7568.
6.
O’Kane, Grainne M., Shereen Ezzat, Anthony M. Joshua, et al.. (2019). A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. British Journal of Cancer. 120(12). 1113–1119.
7.
Percik, Ruth, Gadi Shlomai, Amir Tirosh, et al.. (2019). Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors. Autoimmunity Reviews. 19(2). 102454–102454.
8.
Roszik, Jason, Ettai Markovits, Paula Dobosz, et al.. (2019). TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma. Cancer Immunology Immunotherapy. 68(9). 1493–1500.
9.
Necchi, Andrea, Damien Pouessel, Raya Leibowitz‐Amit, et al.. (2018). Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). Annals of Oncology. 29. viii319–viii320.
10.
Mizrahi, Adi, Aviv Barzilai, Devorah Gur‐Wahnon, et al.. (2017). Alterations of microRNAs throughout the malignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 in epithelial to mesenchymal transition of keratinocytes. Oncogene. 37(2). 218–230.
11.
Goldstein, Jeffrey, Yaacov Richard Lawrence, Benjamin Spieler, et al.. (2017). Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?. Radiation Oncology. 12(1). 5–5.
12.
Abu‐Ghanem, Yasmin, Jacob Ramon, Raanan Berger, et al.. (2017). Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival. World Journal of Surgical Oncology. 15(1). 193–193.
13.
Keizman, Daniel, Keren Rouvinov, Avishay Sella, et al.. (2015). Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?. Cancer Research and Treatment. 48(1). 281–287.
14.
Leibowitz‐Amit, Raya, Jo-An Seah, Eshetu G. Atenafu, et al.. (2014). Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. European Journal of Cancer. 50(14). 2399–2407.
15.
Leibowitz‐Amit, Raya, Özgür Mete, L. Sylvia, Shereen Ezzat, & Anthony M. Joshua. (2014). Malignant Pheochromocytoma Secreting Vasoactive Intestinal Peptide and Response to Sunitinib: A Case Report and Literature Review. Endocrine Practice. 20(8). e145–e150.
16.
Lerman, Galya, Michal Sharon, Raya Leibowitz‐Amit, Yechezkel Sidi, & Dror Avni. (2014). The Crosstalk between IL-22 Signaling and miR-197 in Human Keratinocytes. PLoS ONE. 9(9). e107467–e107467.
17.
Azad, Arun, Bernhard J. Eigl, Raya Leibowitz‐Amit, et al.. (2014). Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. European Urology. 67(3). 441–447.
18.
Templeton, Arnoud J., Francisco Vera-Badillo, L. Wang, et al.. (2013). Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Annals of Oncology. 24(12). 2972–2977.
19.
Avraham, Roi, Aviv Barzilai, Roy Navon, et al.. (2012). Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Molecular Cancer. 11(1). 44–44.
20.
Moalem‐Taylor, Gila, Eti Yoles, Raya Leibowitz‐Amit, et al.. (2000). Autoimmune T cells retard the loss of function in injured rat optic nerves. Journal of Neuroimmunology. 106(1-2). 189–197.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Seunggu J. Han Breakdown of academic impact, for papers by Camilo E. Fadul Breakdown of academic impact, for papers by Michael A. Gordon Breakdown of academic impact, for papers by N. Ferrara Breakdown of academic impact, for papers by Laura Fugazzola Breakdown of academic impact, for papers by Wenche Jy Breakdown of academic impact, for papers by Dirk Walter Breakdown of academic impact, for papers by Elisabeth M. Zeisberg Breakdown of academic impact, for papers by Michael R. Harrison Breakdown of academic impact, for papers by Jun‐ichi Hanai